|
ABEO | Abeona Therapeutics Inc. |
|
|
ABEO | Abeona Therapeutics Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.31 |
| Leverage | 62.04% |
| Market Cap | $ 149.1m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -70.5m |
| Margin | -8421.23% |
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for rare, life-threatening genetic diseases. The company is headquartered in New York, New York.